Phase Ib and Phase II Studies of anti-PD-1 Antibody Pembrolizumab (MK-3475) in Combination with Bevacizumab for the Treatment of Metastatic Renal Cell Carcinoma: Big Ten Cancer Research Consortium BTCRC-GU14-003
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to find the maximum safe dose of pembrolizumab (also known as MK-3475) in combination with bevacizumab that can be given to patients with metastatic clear cell kidney cancer.
Description
The purpose of this study is to determine the activity of the combination of pembrolizumab and bevacizumab in first line therapy for subjects with metastatic clear cell RCC as assessed by response rate.
Details
| Condition | Renal Cell Carcinoma |
|---|---|
| Age | 18years - 100years |
| Clinical Study Identifier | TX5747 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.